Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

Official Title

A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Keywords

Acne Inversa Hidradenitis Suppurativa Hidradenitis

Eligibility

You can join if…

Open to people ages 18-75

  • male or female participants, between 18-75, with a diagnosis of moderate to severe Hidradenitis Suppurativa

You CAN'T join if...

  • History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
  • Infected with hepatitis B or hepatitis C viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Locations

  • UCSF Dermatology Clinic accepting new patients
    San Francisco California 94115 United States
  • University of California San Francisco accepting new patients
    San Francisco California 94115 United States
  • UCSF Psoriasis and Skin Treatment Center accepting new patients
    San Francisco California 94118 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
ID
NCT04092452
Phase
Phase 2
Study Type
Interventional
Last Updated